TY - ADVS
T1 - CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Monday, June 14, 2021 The standard treatment for patients with metastatic urothelial cancer is the combination of gemcitabine and cisplatin. Jonathan E. Rosenberg, MD, and colleagues from Memorial Sloan Kettering Cancer Center, New York, evaluated the impact of adding bevacizumab to the combination treatment and determined that it did not improve overall survival.
PY - 2021/6/14
Y1 - 2021/6/14
N2 - The standard treatment for patients with metastatic urothelial cancer is the combination of gemcitabine and cisplatin. Jonathan E. Rosenberg, MD, and colleagues from Memorial Sloan Kettering Cancer Center, New York, evaluated the impact of adding bevacizumab to the combination treatment and determined that it did not improve overall survival. Their results from the phase III CALGB 90601 trial were published in the Journal of Clinical Oncology.
AB - The standard treatment for patients with metastatic urothelial cancer is the combination of gemcitabine and cisplatin. Jonathan E. Rosenberg, MD, and colleagues from Memorial Sloan Kettering Cancer Center, New York, evaluated the impact of adding bevacizumab to the combination treatment and determined that it did not improve overall survival. Their results from the phase III CALGB 90601 trial were published in the Journal of Clinical Oncology.
UR - https://jnccn360.org/bladder/medical-literature/calgb-90601-combination-gemcitabine-and-cisplatin-with-bevacizumab-in-urothelial-carcinoma/
M3 - Web publication/site
ER -